

Obiltoxaximab SFL (*obiltoksaksimabas*)

CV]hcl UI]a UV'G: @Udýj U[U']f_cX ``^g_Vi j c'fY[]ghfi chUg'gi fcdcg'G `i b[c'Y` (ES)

Kas yra Obiltoxaximab SFL ir kam jis vartojamas?

Obiltoxaximab SFL – HU]j U]ghUgž_i f]g'g_]f]Ua Ug_UfH_ gi 'Ubh]V]ch_U]g]b\U]W]b g'`i cX][gž'VU_hYf]^cg' Bacillus anthracis gi _Y]Ua cg'gi b_]cg`][cgž[mXma i]`p-b\U]W]b f]fY]y]Už'_UX'Uga i c`][U'i ýg]fY]U`_j d g'gdcf z_i f]cg'cf[Ub]na Y]f]fgHU'U_hmj]ca]g'VU_hYf]`ca]g]f]ýg]f]U'Yb_ga]b[i g'hc_g]bi g"

ü]g'j U]ghUg' HU]d'dUh'g_]f]Ua Ug]b\U]W]b g'`i cX][g'dfcZ[U_h]U]ýa cb a gž'_i f]Y'h f 'c'g `m'gi ' VU_hYf]^ gdcfca gž'_U]b fU'c_][_]h 'h]b_Ua [mXma c'df]Ya cb] "

CV]hcl UI]a UV'G: @gi X hM'nfU'j Y]_]cg]cg'a YXY]U[cg'cV]hcl_gU_g]a UVc"

si cX][`nfU'fYH]`][Už'hcX ``&\$%` a "fi [d^`c`(&`X''`CV]hcl UI]a UV'G: @Vi j c'df]g]fHUg'fYh ^ `j U]gh f`ffYhca g`][ca g'[mXmh]g]fh 'j U]gh £_UhY[cf]U]" 8Ui []Ui]bZfa UW]cg'Ud]Y'df]g]mf]a 'fYh]Yg]Ya g` vaistams rUg]h`][U. ema.europa.eu/medicines/human/orphan-designations/eu3182065.

Kaip vartoti Obiltoxaximab SFL?

CV]hcl UI]a UV'G: @[U']a U' g][m1]h]`dUhY]_i g'fYVWdh ">`fY]_U'j Ufhlch]`hc_]c'Y'j]Yh'Yz'_i f'V h`[U']a U' [fY]H]`[mXmh]`gi b_]Ug'U'Yf[]bYg'fYU_W]Ug"

G_]f]Ua U'j]YbU'CV]hcl UI]a UV'G: @]bZ n]Už'_i f]`j Yb`gi 'Uý]bUa U'dYf`- \$`a]bi] "FY_ca YbXi c'Ua U' j U]ghc`Xcn`df]`Ui gc'bi c'dUV]Ybhc`_bc'gj cf]c" Df]Yy'Uý]bUbh'CV]hcl aximab SFL, pacientams galima g_]fh`j U]gh ž'dUXYXUb]`jyj Yb[h'U'Yf[]b]`fYU_W]`UfVU'Ug'dU'Yb[j]bUb] "

8Ui []Ui]bZfa UW]cg'Ud]Y'CV]hcl UI]a UV'G: @j Ufhl`ja `]Yy_c_]h`dU_i ch g`UdY'mY'UfVU'_fY]d_]h g`[mXmh`^ `UfVU'`Ugh]b]b_ "

Kaip veikia Obiltoxaximab SFL?

Gi b]`g'dUXUf]b]j g'gj Y]_UH]`gi _Y]U'`i cX][g'VU_hYf]^ [Ua]bUa Ug'hc_g]bUg'`CV]hcl_gU_g]a UVUg'nfU` a cbc`cb]b]g'Ubh]_bUg`- VU'hma Ugž_i f]g'gi a cXY`j]i chUg' HU]dž'_UX`i b[h g]df]Y'`i cX][g'hc_g]bcž` j UX]bUa c'c`p`i cX][g'UdgUi []b]c'Ubh][Ybcf`_ca dc'bYbhcž`Y]Xy]Ub]c'hc_g]bi]`dUhY_h]` `ghY'Yg` H]_a Uglž'_UX'df]g`i b[g'df]Y'`i cX][g'UdgUi []b]c'Ubh][Ybcž]j U]ghUg'bY'Y]g'hc_g]bi]`dUhY_h]` `cf[Ub]na c` `ghY'Yg`f' HU]d'dU'Yb[j]bg`][cg'g]a dhca i g'UfVU'dUX g`^`jyj Yb[h]"

Kokia Obiltoxaximab SFL nauda nustatymas

F Ya]Ubh]g[hmf]a U]g]gi [nj bU]gž[U]_ca Ug]bi ca cb gž_UX'CV]`hcl UI]a UV'G: @j Y]_ga]b[U]`[mXc`]b\ U]UV]b` i cX`]["5h]Y_Ubh` hmf]a i g]gi `i yg]f h]g]U]g`[nj bU]gž_i f]Ya g'dUg]fY]y_`g]a dhca U]z]y[nj YbUa i a c`fcX`_`g]gj mfUj c`bi c`a Uy]Xui [" \$-60 proc. skiriant Obiltoxaximab SFL ir 0-6 proc. g_]f]Ubh`d`UVVV`fbYh]f` j U]gh t"5h]Y_Ubh`hmf]a z_i f]Ua Y`j U]ghUg`UfVU`d`UVVVUg]bZY_i ch]Ya g`[nj bUa g`Vi j c`g_]f]Ua Ug`df]Yy`dUg]fY]y_]Ubh`g]a dhca Ua gž]y[nj YbUa i a Ug`g]Y_`) \$-100 proc. bUi Xc`Ubh`CV]`hcl UI]a UV'G: @z`df]`Ui gca U]bi c`hc`dYf`_`Y`_U]_c`bi c`i yg]f h]a c`Vi j c`dfUX`Ug`[mXma Ug`g_]f]Ubh`d`UVVV`bY]y[nj Ybc`b` j]YbUg`[nj bUg`

Kokia rizika susijusi su Obiltoxaximab SFL vartojimu?

8 Uyb]Ui g]Ug`CV]`hcl UI]a UV'G: @y`U`i h]b]g`dcj Y]_g]f`[U]b]h]g`dUg]fY]y]h`bY`Xui [`U]d`%`ya c`i`)]y`%`L` mfU`[U]j cg`g`_Ui ga Ugž`dfi f]h]Ug`fb]Yyi mgž`X`][`]b`fb]Yy]h]b]g`V`f]a Uglž`V`f]a Uglž`c]g`mgž`g`_Ui ga Ug`]bž`n]c`g`j`Yh`Y`f`[U]j cg`g]U`[]a Ug`

g]g]Ua`y`U`i h]b]`fY]y]b`[`f`Udf]Vc`_`a`z`Ud]Y`_i f]i cg`dfUbYy]h`[mXUbh`CV]`hcl UI]a UV'G: @z`g`fUy`[U]a U`fUg`_dU`_i ch`g`UdY`mY`

?cX`CV]`hcl UI]a UV'G: @Vi`j`c`fY`[`g]hfi`ch]Ug`9G3

=b\ U]UV]b` i cX`][`nfU`[nj mV]`dUj c`b[U`][Už`bi c`i`f]cg`a`f]y]h`\$ dfcW`i`y]g]f`h]g`^`Bcfg` bUh`fU`g`][cg`dfchf`_`U]`nfU`UVU`fYh]z`Uhg]h]bU`i`y]g]f`gh`[U]a U`VU`h]f`Ug`h]f]Ub`]cg`Y`UVcfU`h]f`c`g`Y`_`i`cX`][`g`i`y`f`Uh]Ug`[U`][V`h`dUg`_`Y`g]h]Ug`f`dYf`h]f`c]f`gh]b]i`g`]ydi`c`j`g`?UXUb`[`]gi`g]f`[]a`g`_U`j`i`g`nfU`dYfbY`m`[`a`Uy`Ugž`c`h]m`_U`i`y`_f`gh`_y`a`cb`Yg`nfU`dYfbY`m`[`dUj`c`b`[Už`y`c`j`U]g]h`hmf]a`g`_g`_y`a`cb`a`g`Uh`h]b`Y`a`Ubca`U`Hmf]a`U`gi`[nj`bU]g`dUfcX`z`_UX`y]g]j`U]gh]Ug`j`Y]_ga`]b`[U`g`bi`c`i`cX`][`g`f`UdgUi`[c`bi`c`a`f]h]Yg`H`_`a`Ug]z`_UX`CV]`hcl`UI`[a`UV'G: @h`_`dU`_dcj`Y`_`h`f`g`f`ya`cb`a`g`GUI`[i`a`c`dcj`f]i`CV]`hcl`UI`[a`UV'G: @y`U`i`h]b]g`dcj`Y`_`g`g`Y`_`]ya`g`ya`cb`a`g`dUdfUghai`yra`lengvas`arba`vidutinio`gi`b`_i`a`c`HcX`U`Ybh`fU`bi`gdfYbX`z`_UX`CV]`hcl`UI`[a`UV'G: @bUi`XU`nfU`X]XYgb`i`y`c`_Y`_Ua`f]n`_z`f`_y`g`[U`][V`h`fY`[`g]hfi`ch]Ug`j`Uf]h]ch`9G`

CV]`hcl`UI`[a`UV'G: @fY`[`g]hfi`ch]Ug`j`y`a`h]b`a`g`g`m`ca`gž`b`Yg`X`][`cg`f`Yh`a`c`f`Yh]b]`df]Yy]Ug`][`Ud]Y`CV]`hcl`UI`[a`UV'G: @bVVi`j`c`a`Ubca`U`[U`h`]y]g]Ua`]cg`]b]Zcfa`UV]`cg`5`[Ybh`fU`_Uga`Yh`dYfy`f`g`j`g`bUi`U`[U`h`]b]Zcfa`UV]`f]f`df]fY`_i`g`UhbUi`_`bg`y`_`Ud]yj`U`["

?c`_U`_b]Zcfa`UV]`U`XU`h`f`V`h`dU]h]Y`CV]`hcl`UI`[a`UV'G: @3

?UXUb`[`CV]`hcl`UI`[a`UV'G: @fY`[`g]hfi`ch]Ug`j`y`a`h]b`a`g`g`m`ca`gž`CV]`hcl`UI`[a`UV'G: @`[Ua`]b]Ubh`_VYbXfc`_z`j`m`XmXua`U`UVcfU`h]f`b]i`g`hmf]a`i`g`dU]h]_g`dUd]Xca`Xi`ca`Yb`_`Ud]Y`h]U`_`Ud`y]g`j`U]gh]Ug`UVgcfVi`c`Ua`Ugž`a`cX]_i`c`Ua`Ug`f`y]U`b]Ua`Ug`j`y`c]f`[Ub]na`c`6`Y`h]z`h`f`g`V`h`dU]h]_h`Xi`ca`Ynys`apie`j`U]g]h`j`Y]_ga`b`[i`a`f`g]U`[i`a`dfUg]X`i`g`[U`a`Ua`i`cX`][`g`dfchf`_`j`]"

?c`_cg`df]`Ya`cb`g`h]U`_ca`cg`g]Y`_Ubh`i`y]h`f`b]h`g]U`[`f`j`Y]_ga`]b`[CV]`hcl`UI`[a`UV'G: @j`Uf]h`_`ja`3

?dfYdUfUhc`WUfU`h]f`gh`_`g]Ubh]f]U`_`f`dU`_i`ch`g`UdY`_`h]f]U`_`h]f`g]g]U`[U`g`f`j`Yiksmingo`Obiltoxaximab`G: @j`Uf]h`_`ja`c`fY`_ca`YbXUV]`cg`f`Uhg]U`[i`a`c`df]Y`a`cb`gž`_i`f`_h`f`_`a`h]g`g]Y`_Uhg`df]Y`f`fcg`gdYV]`g]U`ir`pacientai.

?U]d`f`j`g`_j`U]gh`z`CV]`hcl`UI`[a`UV'G: @j`Uf]h`_`ja`c`Xi`ca`Ybm`nfU`bi`c`Uhg`gh]V`a`j`CV]`hcl`UI`[a`UV'G: @`y`U`i`h]b]g`dcj`Y`_`g`_f`cdy`[U`j`Yfh]b]Ua`Ug`_`f`_`a`Ua`Ug`_`j`g`f`Y`_`Ua`_`df]Y`a`cb`_`dU]Wb]Ua`g`Udg]U`[ch`"

Kita informacija apie Obiltoxaximab SFL

Šis vaistinis preparatas yra neberegistravotas Lietuvos Respublikos sveikatos apsaugos ministerijos.
Obiltoxaximab SFL (obiltoksaksimabas)

Vaistinis preparatas neberegistravotas